Cargando…
Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis
BACKGROUND: Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNFα) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant. METHODS: We performed a retrospective chart review to investigate outcome...
Autores principales: | Parekh, Ravish, Abdulhamid, Ahmed, Trudeau, Sheri, Kaur, Nirmal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976998/ https://www.ncbi.nlm.nih.gov/pubmed/29862092 http://dx.doi.org/10.1155/2018/1015408 |
Ejemplares similares
-
Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature
por: Parekh, Ravish, et al.
Publicado: (2014) -
Primary Sclerosing Cholangitis with Inflammatory Bowel Disease in Korean Children
por: Yoon, Jisun, et al.
Publicado: (2015) -
Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review
por: Da Cunha, Teresa, et al.
Publicado: (2022) -
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
por: Kim, You Sun, et al.
Publicado: (2023) -
Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis
por: Mouchli, Mohamad A, et al.
Publicado: (2018)